Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Fangtong Liu, Chao-Ling Wan, Yu-Qing Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zihao Wang, Sheng-Li Xue, Haiping Dai

Blood (2024) 144 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2024-202500

Published: 2024

Journal Articles

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Yunju Ma, Qingya Cui, Chunxiu Yang, Wei Cui, Mengyun Li, Zheng Li, Haiping Dai, Liqing Kang, Lei Yu, Zaixiang Tang, Jianxin Fu, Min Jiang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 683.

https://doi.org/10.1182/blood-2024-209249

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Zihao Wang, Shuai-Shuai Ge, Miao Wang, Haiping Dai, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1527.

https://doi.org/10.1182/blood-2024-197933

Published: 2024

Journal Articles

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Jia Yin, Qingya Cui, Haiping Dai, Zheng Li, Liqing Kang, Wei Cui, Xiaopeng Tian, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2024-207197

Published: 2024

Journal Articles

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Yue Zhou, Juan Chen, Qingya Cui, Haiping Dai, Zheng Li, Jia Yin, Wei Cui, Mengyun Li, Xuekai Li, Xin Zhang, Feiran Gong, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2024-199119

Published: 2024

Journal Articles

Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial

Man Qiao, Suning Chen, Ying Wang, Shengli Xue, Xiaofei Yang, Depei Wu, Huiying Qiu, Yue Han, Yanming Zhang, Kourong Miao, Jihao Zhou, Xiaojin Wu, Miao Miao, Tao You, Xiao Ma, Haiping Dai

Blood (2024) 144 (Supplement 1): 4893.

https://doi.org/10.1182/blood-2024-207338

Published: 2024

Journal Articles

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Blood (2024) 144 (Supplement 1): 971.

https://doi.org/10.1182/blood-2024-202801

Published: 2024

Journal Articles

Safety and Efficacy of Blinatumomab and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Chong-Sheng Qian, Zihao Wang, Lan Dai, Li Yao, Zhen Yao, HaiXia Zhou, Mingzhu Xu, Wenjie Gong, Zheng Li, Haiping Dai, Aining Sun, Depei Wu, Shengli Xue

Blood (2024) 144 (Supplement 1): 5878.

https://doi.org/10.1182/blood-2024-205115

Published: 2024

Journal Articles

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Tong-Tong Zhang, Kai-Wen Tan, Yan Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Songbai Liu, Qiao-Cheng Qiu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2023-185390

Published: 2023

Journal Articles

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Yan-yan Li, Hai-xia Zhou, Si-man Huang, Chao-Ling Wan, Ming-zhu Xu, Wen-jie Gong, Chong-Sheng Qian, De-pei Wu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2023-185312

Published: 2023

Journal Articles

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Liqing Kang, Shengli Xue, Xiaowen Tang, Xiaoyan Lou, Chongsheng Qian, Wenjie Gong, Mingzhu Xu, Haixia Zhou, Zhen Yao, Wei Wang, Minghao Li, Nan Xu, Zhou Yu, Suning Chen, Huiying Qiu, Haiping Dai, Yang Xu, Depei Wu, Lei Yu

Blood (2023) 142 (Supplement 1): 3477.

https://doi.org/10.1182/blood-2023-181552

Published: 2023

Journal Articles

Venetoclax Combined with Hypomethylation Agents As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia - Priliminary Results from a Real World Study in China

Haiping Dai, Jia Chen, Xiebing Bao, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2023-189654

Published: 2023

Journal Articles

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Blood (2023) 142 (Supplement 1): 889.

https://doi.org/10.1182/blood-2023-172615

Published: 2023

Journal Articles

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Blood (2023) 142 (15): 1323–1327.

https://doi.org/10.1182/blood.2023020102

Published: 2023

Includes: Supplemental data

Journal Articles

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Qian Wang, Haiping Dai, Wenzhi CAI, Qinrong Wang, Zhu Mingqing, Lingzhi Yan, Yan Yu, Hongjie Shen, Yang Xu, Ying Wang, Miao Miao, Shengli Xue, Yue Han, Xiaowen Tang, Huiying Qiu, Aining Sun, Jinyan Huang, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 9198–9200.

https://doi.org/10.1182/blood-2022-156862

Published: 2022

Journal Articles

Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 Mutations in Hematological Malignancies

Shuai-Shuai Ge, Xiangdong Shen, Tianmei Wu, Jiahui Du, Haiping Dai, Qiaocheng Qiu, Songbai Liu, Depei Wu, Shengli Xue

Blood (2022) 140 (Supplement 1): 1425–1426.

https://doi.org/10.1182/blood-2022-159960

Published: 2022

Journal Articles

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haiping Dai, Wei Cui, Hongjie Shen, Qian Wang, Jia Yin, Zheng Li, Depei Wu, Xiaowen Tang

Blood (2022) 140 (Supplement 1): 10345–10346.

https://doi.org/10.1182/blood-2022-166687

Published: 2022

Journal Articles

Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study

Yanyan Li, Haixia Zhou, Chaoling Wan, Mingzhu Xu, Chongsheng Qian, Tongtong Zhang, Haiping Dai, AiNing Sun, Depei Wu, Shengli Xue

Blood (2022) 140 (Supplement 1): 3212–3213.

https://doi.org/10.1182/blood-2022-168054

Published: 2022

Journal Articles

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Haiping Dai, Yang Lin, Huimin Meng, Qingya Cui, Wenjuan Zhu, Xiaowen Tang, Wei Cui, Depei Wu

Blood (2021) 138 (Supplement 1): 4817.

https://doi.org/10.1182/blood-2021-151587

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Lei Yu, Liqing Kang, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2021-152565

Published: 2021

NARROW

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Safety and Efficacy of Blinatumomab and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Venetoclax Combined with Hypomethylation Agents As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia - Priliminary Results from a Real World Study in China

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 Mutations in Hematological Malignancies

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only